{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:14:10Z","timestamp":1771578850852,"version":"3.50.1"},"reference-count":12,"publisher":"BMJ","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gut"],"published-print":{"date-parts":[[1992,9]]},"abstract":"<jats:p>A total of 9928 cimetidine users were identified from prescriptions in four centres and followed for 10 years. The 'all-cause' mortality ratio fell from 1.9 in year 1 to 1.0 in years 8 to 10. Most of the early excess in mortality was attributable to cimetidine being given in the late stages of many diseases, often to counter adverse gastric effects of other drugs. Specific causes of mortality during years 5-10 of the study, were generally unremarkable. Significant increases in mortality ratios were apparent, however, for oesophageal cancer (years 5-7, 2.3; years 8-10, 1.9); lung cancer (years 5-7, 1.1; years 8-10, 1.7); diseases of the oesophagus, stomach, and duodenum (years 5-7, 3.3; years 8-10, 2.3); and chronic liver disease (years 5-7, 2.4; years 8-10, 3.3). None of these increases in mortality seems to be attributable to an adverse effect of cimetidine use. Data are also presented for mortality from diseases of the nervous system. Eight deaths (of which one was miscoded) were certified as being from motor neurone disease, representing a mortality ratio of 2.6 for years 2-10 of the study which is of borderline statistical significance. This study confirms that cimetidine is safe. Mortality from some diseases increased over the study period, but selection rather than any adverse effect of the drug is likely to be the explanation.<\/jats:p>","DOI":"10.1136\/gut.33.9.1280","type":"journal-article","created":{"date-parts":[[2007,9,18]],"date-time":"2007-09-18T17:41:31Z","timestamp":1190137291000},"page":"1280-1284","source":"Crossref","is-referenced-by-count":45,"title":["Postmarketing surveillance of the safety of cimetidine: 10 year mortality report."],"prefix":"10.1136","volume":"33","author":[{"given":"D G","family":"Colin-Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Langman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D H","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R F","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K R","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M P","family":"Vessey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1992,9,1]]},"reference":[{"key":"ref_1","first-page":"13113","article-title":"Cimetidine use and gastric cancer: a preliminary report from a postmarketing surveillance study","volume":"285","author":"Colin-Jones, D.G.; Langman, M.J.S.; Lawson, D.H.; Vessey, M.P.","year":"1982","unstructured":"Colin-Jones DG, Langman MJS, Lawson DH, Vessey MP. Cimetidine use and gastric cancer: a preliminary report from a postmarketing surveillance study. BMJ 1982; 285: 13113.","journal-title":"BMJ"},{"key":"ref_2","first-page":"13","article-title":"Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus","volume":"285","author":"Colin-Jones, D.G.; Langman, M.J.S.; Lawson, D.H.; Logan, R.F.A.; Paterson, K.R.; Vessey, M.P.","year":"1991","unstructured":"Colin-Jones DG, Langman MJS, Lawson DH, Logan RFA, Paterson KR, Vessey MP. Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus. QJ Med 1991; 285: 13-9.","journal-title":"QJ Med"},{"key":"ref_3","first-page":"1713","article-title":"Postmarketing surveillance of the safety of","volume":"286","author":"Colin-Jones, D.G.; Langman, M.J.S.; Lawson, D.H.; Vessey, M.P.","year":"1983","unstructured":"Colin-Jones DG, Langman MJS, Lawson DH, Vessey MP. Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. BMJ 1983; 286: 1713-6."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/bmj.291.6502.1084","article-title":"Postmarketing surveillance of the safety of cimetidine: mortality during second, third and fourth years of follow-up","volume":"291","author":"Cohn-Jones, D.G.; Langman, M.J.S.; Lawson, D.H.; Vessey, M.P.","year":"1985","unstructured":"Cohn-Jones DG, Langman MJS, Lawson DH, Vessey MP. Postmarketing surveillance of the safety of cimetidine: mortality during second, third and fourth years of follow-up. BMJ 1985; 291: 1084-8.","journal-title":"BMJ"},{"key":"ref_5","first-page":"253","article-title":"Postmarketing surveillance of the safety of","volume":"54","author":"Colin-Jones, D.G.; Langman, M.J.S.; Lawson, D.H.; Vessey, M.P.","year":"1985","unstructured":"Colin-Jones DG, Langman MJS, Lawson DH, Vessey MP. Postmarketing surveillance of the safety of cimetidine: 12 month morbidity report. Qj Med 1985; 54: 253-68.","journal-title":"Qj Med"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0140-6736(90)91888-H","article-title":"Histamine-2-receptor antagonists and gastric cancer risk","volume":"336","author":"C, La Vecchia; E, Negri; B, D.'Avanzo; S, Franceschi","year":"1990","unstructured":"La Vecchia C, Negri E, D'Avanzo B, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet 1990; 336: 355-7.","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/gut.30.11.1558","article-title":"Cancer occurrence in a cohort of patients treated with cimetidine","volume":"30","author":"Moller, H.; Lindvig, K.; Klefter, R.; Mosbech, J.; Jensen, O.M.","year":"1989","unstructured":"Moller H, Lindvig K, Klefter R, Mosbech J, Jensen OM. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989; 30: 1558-62.","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0016-5085(19)31847-5","article-title":"Bonnevie 0, Causes of death in duodenal and gastric ulcer","volume":"73","year":"1977","unstructured":"Bonnevie 0, Causes of death in duodenal and gastric ulcer. Gastroenterology 1977; 73: 1000-4.","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(76)92790-2","article-title":"Gastric and duodenal ulcer and their associated diseases","volume":"i:","author":"Langman, M.J.S.; Cooke, A.R.","year":"1976","unstructured":"Langman MJS, Cooke AR. Gastric and duodenal ulcer and their associated diseases. Lancet 1976; i: 680-3.","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM198208263070902","article-title":"Late mortality after surgery for peptic ulcer","volume":"307","author":"Ross, A.H.M.; Smith, M.A.; Anderson, JR, Small; W.P.","year":"1982","unstructured":"Ross AHM, Smith MA, Anderson JR, Small WP. Late mortality after surgery for peptic ulcer. N EnglJf Med 1982; 307: 519-22.","journal-title":"N EnglJf Med"},{"key":"ref_11","first-page":"644","article-title":"Xenobiotic metabolism in motorneurone disease","volume":"ii:","author":"Steventon, G.; Williams, A.C.; Waring, R.H.; Pall, H.S.; Adams, D.","year":"1988","unstructured":"Steventon G, Williams AC, Waring RH, Pall HS, Adams D. Xenobiotic metabolism in motorneurone disease. Lancet 1988; ii: 644-7.","journal-title":"Lancet"},{"key":"ref_12","first-page":"1453","article-title":"Alzheimer's disease in antacid users","volume":"334","author":"Colin-Jones, D.G.; Langman, M.J.S.; Lawson, D.H.; Vessey, M.P.","year":"1989","unstructured":"Colin-Jones DG, Langman MJS, Lawson DH, Vessey MP. Alzheimer's disease in antacid users. Lancet 1989; 334: 1453.","journal-title":"Lancet"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gut.33.9.1280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T16:12:21Z","timestamp":1765642341000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gut.33.9.1280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,9]]},"references-count":12,"journal-issue":{"issue":"9","published-online":{"date-parts":[[1992,9,1]]},"published-print":{"date-parts":[[1992,9]]}},"alternative-id":["10.1136\/gut.33.9.1280"],"URL":"https:\/\/doi.org\/10.1136\/gut.33.9.1280","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,9]]}}}